Hims & Hers Health Inc. is expanding into lab testing services as part of its growing focus on preventive healthcare, according to Dow Jones.

U.S.-listed shares of the company rose 6% in premarket trading.

The telehealth platform will allow customers to access testing at more than 1,000 Quest Diagnostics locations nationwide. After testing, users will receive results and consult with providers on the Hims & Hers platform to develop personalized health plans that may include prescriptions, supplements, or nutrition guidance.

The company offers two pricing tiers: a $199 annual plan for one blood draw covering 50 biomarker tests, and a $499 plan that includes two blood draws and 120 biomarker tests. These tests evaluate various health aspects including heart health, metabolism, hormones, inflammation, and stress.

Chief Executive Andrew Dudum believes the service will be accessible to most Americans. "It’s a price point that I think the majority of the country can afford," he said.

Dudum expects this preventive care initiative to attract new users beyond the company’s established customer base for hair loss, weight loss, and sexual health treatments. He projects the lab testing service will eventually grow into a $1 billion business.

"You know, size of this market is, I think every single person in the country," Dudum stated regarding the potential reach of the new offering.